Intelligence for Neurology Specialists

Neurology clinical trials
recruiting in the United States

Up-to-date overview of clinical trials in Parkinson's disease, Alzheimer's, dementia, epilepsy, multiple sclerosis and other neurological conditions recruiting patients in the United States — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centers.

125

Active trials

1259

US sites

Indications covered

BR trials

Loading map…

125 studies found

N/DTumores do Sistema Nervoso CentralTumores de Nervos PerifericosEpilepsiaUS 1 site in the US

Evaluation and Treatment of Neurosurgical Disorders

National Institute of Neurological Disorders and Stroke (NINDS)

📍 Bethesda👥 5000 participants

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple SclerosisAlzheimerUS 1 site in the US

Microglial Activation PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Brigham and Women's Hospital

📍 Boston👥 250 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Falha Autonomica PuraAtrofia de Multiplos SistemasDoenca de ParkinsonUS 1 site in the US

The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2

Vanderbilt University Medical Center

📍 Nashville👥 34 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DEnvelhecimento NormalDoenca de ParkinsonUS 2 sites in the US

Pilot Intervention With Near Infrared Stimulation: Revitalizing Cognition in Older Adults and Those With Parkinson Disease

University of Florida

📍 Gainesville, Tucson👥 24 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Cancer de ProstataUS 1 site in the US

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Mark Garzotto, MD

📍 Portland👥 32 participants📅 Completion: 2023-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Alzheimer DiseaseUS 1 site in the US

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

Mayo Clinic

📍 Jacksonville👥 614 participants📅 Completion: 2030-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DSleep Dependent LearningUS 1 site in the US

What is Sleep's Role in Alzheimer's Disease? Insight From Healthy Aging

University of Massachusetts, Amherst

📍 Amherst👥 584 participants📅 Completion: 2025-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Age Related Cognitive DeclineAlzheimer Disease And Related DementiasUS 4 sites in the US

Cognitive Training to Reduce Incidence of Cognitive Impairment in Older Adults

University of South Florida

📍 Durham, Sarasota, Seneca, Tampa👥 7600 participants📅 Completion: 2026-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimer DiseaseComprometimento CognitivoDeclinio CognitivoUS 1 site in the US

The BEACoN Study- Biomarker Exploration in Aging, Cognition and Neurodegeneration

University of California, Irvine

📍 Irvine👥 300 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseMild Cognitive ImpairmentNeuropsychiatric SymptomsUS 1 site in the US

Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia

Stanford University

📍 Palo Alto👥 150 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Stimulation of the External Pallidal Segment for Insomnia in Patients With Parkinson's Disease

Mayo Clinic

📍 Jacksonville👥 10 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DPerda Auditiva SensorioneuralDemencia de AlzheimerComprometimento Cognitivo Leve AmnesticoUS 2 sites in the US

Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia

Northwestern University

📍 Chicago, Evanston👥 20 participants📅 Completion: 2025-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Falha Autonomica PuraDoenca de ParkinsonAtrofia de Multiplos SistemasUS 1 site in the US

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Daniel Claassen

📍 Nashville👥 40 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Autoimmune DiseasesCardiovascular DisordersDiabetes ComplicationsUS 1 site in the US

Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions

Thomas Advanced Medical LLC

📍 Culver City👥 5000 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons DiseaseTremor EssencialDistoniaUS 1 site in the US

Investigating Inhibitory Control Networks in Parkinson's Disease

University of Alabama at Birmingham

📍 Birmingham👥 140 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Alzheimer DiseaseUS 1 site in the US

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Baylor College of Medicine

📍 Houston👥 52 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DMild Cognitive ImpairmentAlzheimer DiseaseUS 1 site in the US

Promoting Independence With Compensatory Cognitive Rehabilitation: A Pilot Clinical Trial for Early-Stage Alzheimer's Disease

University of Delaware

📍 Newark👥 65 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Major Depressive DisorderAlzheimer DiseaseUS 2 sites in the US

Depression Treatment and Aβ Dynamics: A Study of Alzheimer's Disease Risk (ABD Study)

NYU Langone Health

📍 New York, Orangeburg👥 60 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer Disease And Related DementiasCaregiver BurdenUS 4 sites in the US

Decision-Making Experiences for Culturally Inclusive Dementia Engagement: Dyads and Families (DECIDE: Dyads and Families)

Emory University

📍 Atlanta, Washington D.C.👥 40 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Non Small Cell Lung CancerUS 5 sites in the US

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

BioNTech SE

📍 Baltimore, Fairfax, Houston, Lexington, Louisville👥 320 participants📅 Completion: 2031-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Doenca de ParkinsonUS 2 sites in the US

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)

Gateway Institute for Brain Research

📍 Davie, Hialeah👥 56 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseControle SaudavelUS 1 site in the US

Plasticity of Motor Systems in Early Stage Parkinson's Disease

University of Minnesota

📍 Minneapolis👥 50 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Parkinson DiseaseParkinson Disease PsychosisDemencia de Corpos de LewyUS 1 site in the US

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Vanderbilt University Medical Center

📍 Nashville👥 75 participants📅 Completion: 2026-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Amyotrophic Lateral SclerosisAlzheimer DiseaseMultiple SclerosisUS 3 sites in the US

A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers

Ashvattha Therapeutics, Inc.

📍 Jacksonville, San Francisco, Stanford👥 65 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DDoenca de ParkinsonHipotensao OrtostaticaDisautonomiaUS 1 site in the US

Effects of Blood Pressure on Cognition and Cerebral Blood Flow in Parkinson Disease

University of California, San Diego

📍 San Diego👥 60 participants📅 Completion: 2026-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DDepressionUS 1 site in the US

The Impact of Depression and Preclinical Alzheimer Disease on Driving Among Older Adults (Depression and Driving)

Ganesh Babulal

📍 St Louis👥 150 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons DiseaseUS 1 site in the US

Udall Project 1 Aim 4

University of Minnesota

📍 Minneapolis👥 100 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer Disease Early OnsetUS 1 site in the US

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

Indiana University

📍 Indianapolis👥 60 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DAgingAlzheimer DiseaseUS 1 site in the US

Losing Specificity: the Role of the Locus Coeruleus in Age-related Distractibility

Virginia Polytechnic Institute and State University

📍 Blacksburg👥 200 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseDemencia VascularDemencia MistaUS 3 sites in the US

Hybrid Efficacy-effectiveness Trial to Promote Goals-of-care Discussions for Patients With Alzheimer's Disease and Related Dementias and Their Family Caregivers

University of Washington

📍 Seattle👥 1800 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseUS 1 site in the US

Development of a Personalized Intervention to Motivate Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease

Rhode Island Hospital

📍 Providence👥 40 participants📅 Completion: 2025-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimers DiseaseUS 2 sites in the US

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

University of Pennsylvania

📍 Boston, Philadelphia👥 100 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Exercise for Cognitive Excellence in Parkinson's Disease

University of California, San Francisco

📍 San Francisco👥 32 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DMinorias Sexuais e de GeneroHospice Cuidados PaliativosAlzheimer e Demencias RelacionadasUS 1 site in the US

A Novel Intervention to Improve Care for Older Sexual and Gender Minority (SGM) Adults With Serious Illness and Especially Those With Alzheimer's Disease and Related Dementias (ADRD)

University of Colorado, Denver

📍 Aurora👥 80 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Parkinson DiseaseUS 1 site in the US

Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder

University of Minnesota

📍 Minneapolis👥 60 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DDeliriumMild Cognitive ImpairmentAlzheimer DiseaseUS 7 sites in the US

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders (ENHANCE)

University of Michigan

📍 Ann Arbor, Madison, Orange, Philadelphia, Pittsburgh, Portland, Salt Lake City👥 1900 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DSedentarismo e Inatividade FisicaObesidadeUS 1 site in the US

Goal Setting to Promote Physical Activity Adherence in Midlife to Reduce Risk of Alzheimer's Disease and Related-Dementias: A Randomized Mechanistic Proof-Of-Concept Trial

Arizona State University

📍 Phoenix👥 144 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseUS 1 site in the US

Gamma-Music Based Intervention for Mild Alzheimer's Disease

Northeastern University

📍 Boston👥 60 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2OsteoporosisUS 1 site in the US

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease

Duke University

📍 Durham👥 45 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Alzheimer DiseaseUS 1 site in the US

A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease

The Methodist Hospital Research Institute

📍 Houston👥 40 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Parkinsons DiseaseMultiple System AtrophyDementia With Lewy BodiesUS 1 site in the US

PET Imaging Evaluation of [11C]SY08

Massachusetts General Hospital

📍 Charlestown👥 40 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DMild Cognitive ImpairmentAlzheimer Disease And Related DementiasPerda AuditivaUS 2 sites in the US

Over-the-counter Hearing Aids and Mild Cognitive Impairment

Northwestern University

📍 Evanston, Madison👥 50 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseUS 1 site in the US

Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

Washington University School of Medicine

📍 St Louis👥 80 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Utilization of Robotic EksoSkeleton to Achieve High Dosing, Intensity, and Complexity of Gait in Treatment of People With Parkinson's Disease

Albert Einstein Healthcare Network

📍 Elkins Park👥 24 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer Disease And Related DementiasCancerUS 1 site in the US

Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision

University of Rochester

📍 Rochester👥 300 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Alzheimer DiseaseAlzheimer Dominante Autossomico Psen1Alzheimer Dominante Autossomico Psen2US 1 site in the US

A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics

University College, London

📍 St Louis👥 10 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DParagangliomaFeocromocitomaEsclerose Lateral AmiotroficaUS 1 site in the US

Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System

University of Pennsylvania

📍 Philadelphia👥 1000 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DComprometimento Cognitivo LeveDoenca de AlzheimerUS 1 site in the US

Proof of Concept of the Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

NeuroVision Imaging

📍 Sacramento👥 200 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DCritical IllnessDeliriumComprometimento CognitivoUS 1 site in the US

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

University of Washington

📍 Seattle👥 100 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseUS 1 site in the US

Beta Amyloid PET Imaging for Alzheimer Disease: [18F]-Fluselenamyl (Alternative Vehicle) Comparison With [11C]-PIB (FSA-PIB AD)

Washington University School of Medicine

📍 St Louis👥 60 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Genetics and Aerobic Exercise to Slow Parkinson's Disease (GEARS) Trial

Jay Alberts

📍 Cleveland👥 200 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Social Prescription for Loneliness in Community-based Group Exercise Classes for People With Parkinson Disease

Colorado State University

📍 Fort Collins👥 40 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Parkinsons DiseaseDepressaoUS 1 site in the US

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Joshua Woolley, MD, PhD

📍 San Francisco👥 60 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Revealing the Action Regulation Mechanisms in the Human Brain

University of Texas Southwestern Medical Center

📍 Dallas👥 50 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons DiseaseUS 1 site in the US

Blood Flow Restriction for Optimizing Balance in Parkinson's Disease

The University of Texas Health Science Center at San Antonio

📍 San Antonio👥 20 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Comprometimento Cognitivo LeveAlzheimerUS 1 site in the US

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

University of California, San Diego

📍 San Diego👥 60 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Remote Monitoring Using Commercially Available Activity Trackers and Computer Vision Provides a Holistic, Low-cost Assessment of Parkinson's Disease Symptoms

Jacob E. Simmering

📍 Iowa City👥 120 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Parkinsons DiseaseUS 7 sites in the US

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Denali Therapeutics Inc.

📍 Boca Raton, Boston, Kirkland, Los Angeles, New York, San Francisco, Spokane👥 50 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2StrokeParkinson DiseaseDisfagiaUS 1 site in the US

Impact of Wearable Biofeedback for the Rehabilitation and Tele-rehabilitation of Neurogenic Dysphagia

Purdue University

📍 West Lafayette👥 120 participants📅 Completion: 2029-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Parkinson DiseaseUS 1 site in the US

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Vikas Kotagal

📍 Ann Arbor👥 102 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Doenca de ParkinsonUS 42 sites in the US

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)

Neuron23 Inc.

📍 Atlanta, Augusta, Aurora, Baltimore, Boca Raton, Boston, Chapel Hill, Charleston👥 150 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

University of Minnesota

📍 Minneapolis👥 25 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseComprometimento Cognitivo LeveDemenciaUS 1 site in the US

Duke/UNC Alzheimer's Disease Center Clinical Cohort

Duke University

📍 Durham👥 500 participants📅 Completion: 2026-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseUS 1 site in the US

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

University of Kansas Medical Center

📍 Fairway👥 288 participants📅 Completion: 2029-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Parkinsons DiseaseUS 2 sites in the US

A Multicenter, Sham-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Responses Following Stereotactic Intracranial Implantation of DSP-1083 Into Subjects With Parkinson's Disease

Sumitomo Pharma America, Inc.

📍 Lexington, New York👥 25 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Parkinsons DiseaseUS 23 sites in the US

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

Impax Laboratories, LLC

📍 Aliso Viejo, Aventura, Boca Raton, Canton, Cincinnati, Cleveland, Commack, Dallas👥 220 participants📅 Completion: 2026-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Parkinsons DiseaseUS 14 sites in the US

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants With Parkinson's Disease

TrueBinding, Inc.

📍 Aliso Viejo, Boca Raton, Commack, Englewood, Farmington Hills, Indianapolis, Kansas City, Miami👥 62 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DMild Cognitive ImpairmentAlzheimer DementiaTraumatic Brain InjuryUS 1 site in the US

Mechanisms of Mindfulness for Cognition in Early-Stage Alzheimer's Disease

VA Boston Healthcare System

📍 Boston👥 100 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons DiseaseUS 1 site in the US

Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson's Disease

Brigham and Women's Hospital

📍 Boston👥 6 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Parkinson DiseaseUS 1 site in the US

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Eli Lilly and Company

📍 Austin👥 127 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseDemenciaUS 1 site in the US

Transitional Care for Skilled Nursing Facility Patients With Alzheimer's Disease and Related Dementias and Their Caregivers: a Cluster Randomized Trial

University of North Carolina, Chapel Hill

📍 Chapel Hill👥 360 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 1 site in the US

Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease

St. Louis University

📍 St Louis👥 40 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseEssential TremorUS 1 site in the US

Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease

University of Nebraska

📍 Omaha👥 138 participants📅 Completion: 2028-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseDemenciaPerda AuditivaUS 1 site in the US

HEARS Neuropsychiatric Symptoms & Hearing Loss: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

Johns Hopkins University

📍 Baltimore👥 300 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimer DiseaseAgitacao em AlzheimerAgitacao em DemenciaUS 8 sites in the US

A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)

Bristol-Myers Squibb

📍 Bountiful, Carrollton, Miami, Morehead City, Newton, Port Orange, Scottsdale, Tampa👥 600 participants📅 Completion: 2029-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Parkinsons DiseaseUS 28 sites in the US

exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease

BlueRock Therapeutics

📍 Ann Arbor, Aurora, Baltimore, Boston, Buffalo, Burlington, Charleston, Chicago👥 102 participants📅 Completion: 2032-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Parkinson DiseaseUS 15 sites in the US

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Biohaven Therapeutics Ltd.

📍 Atlantis, Bellevue, Birmingham, Boca Raton, Boston, Chesterfield, Chicago, Farmington👥 550 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DDor CronicaDepressaoAnsiedadeUS 1 site in the US

Evaluating and Optimizing Just-In-Time Adaptive Interventions (JITAIs) in a Digital Mental Health Intervention (Wysa for Chronic Pain) for Middle-Aged and Older Adults With Chronic Pain

Washington University School of Medicine

📍 St Louis👥 1000 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Cancer de EndometrioEndometrial CancerUS 29 sites in the US

DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

AstraZeneca

📍 Arlington Heights, Augusta, Austin, Baltimore, Boston, Charlotte, Charlottesville, Cincinnati👥 600 participants📅 Completion: 2031-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons DiseaseUS 1 site in the US

Imaging Core Aim 2, and Udall Project 2 Aim 2

University of Minnesota

📍 Minneapolis👥 20 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons Disease IdiopaticaUS 1 site in the US

Effects of Deep Brain Stimulation (DBS) on Laryngeal Function and Associated Behaviors in Parkinson Disease

University of Florida

📍 Gainesville👥 100 participants📅 Completion: 2029-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DEnvelhecimentoUS 1 site in the US

Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)

National Institute on Aging (NIA)

📍 Baltimore👥 400 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Parkinson Disease Com Comprometimento Cognitivo LeveDemencia da Doenca de ParkinsonUS 1 site in the US

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

Prabesh Kanel

📍 Ann Arbor👥 45 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimers DiseaseUS 31 sites in the US

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

Hoffmann-La Roche

📍 Arlington, Atlantis, Beaumont, Boston, Chicago, Clermont, Dallas, Decatur👥 800 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DMild Cognitive ImpairmentMild Alzheimer DiseaseUS 1 site in the US

A Pilot Study To Assess The Dynamic Difficulty Adjustment In Personalized Testing For Persons With MCI And Matched Healthy Controls

Indivi AG

📍 Boston👥 55 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimers DiseaseUS 68 sites in the US

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

Hoffmann-La Roche

📍 Albuquerque, Arlington, Atlanta, Atlantis, Beaumont, Birmingham, Boston, Brownsville👥 13000 participants📅 Completion: 2035-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons DiseaseParkinsons Disease DementiaAlzheimers DiseaseUS 1 site in the US

Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases.

Sanmai Technologies PBC dba Sanmai

📍 Santa Monica👥 20 participants📅 Completion: 2026-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DDoenca de ParkinsonControle SaudavelUS 1 site in the US

The Effects of Vagus Nerve Stimulation on Intrinsic Lower Leg Spinal Motoneuron Excitability in Parkinson's Disease.

University of Minnesota

📍 Minneapolis👥 75 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Alzheimer DiseaseUS 1 site in the US

An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)

NKGen Biotech, Inc.

📍 Glendale👥 30 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseOutras DemenciasUS 1 site in the US

Feasibility and Effect of Remotely Supervised Transcranial Direct Current Stimulation With Chair Yoga for Chronic Knee Pain Management in Older Adults With Alzheimer's Disease and Related Dementias.

University of Arizona

📍 Tucson👥 40 participants📅 Completion: 2026-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons DiseaseUS 1 site in the US

Electrophysiology-based Deep Brain Stimulation Programming for Parkinson's Disease

University of Florida

📍 Gainesville👥 30 participants📅 Completion: 2031-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DDoenca de ParkinsonUS 1 site in the US

Comparison of Changes in Neuromuscular and Functional Performance Due to Resistance Training With Low-Load or High-Load in Persons With Parkinson's Disease.

University of Miami

📍 Coral Gables👥 60 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinsons DiseaseUS 1 site in the US

Relationship Between Speech Perceptual Learning and Speech Production in Parkinson's Disease

State University of New York at Buffalo

📍 Buffalo👥 50 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DDemenciaAlzheimerEstresse do CuidadorUS 1 site in the US

A Randomized Controlled Trial of a Care Partner-Centered Structured Retrieval Practice Intervention for Dementia Caregiver Education and Well-Being

Virginia Wesleyan University

📍 Virginia Beach👥 65 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DEssential TremorEssential Tremor PlusUS 1 site in the US

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

CND Life Sciences

📍 Scottsdale👥 300 participants📅 Completion: 2029-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Psicose Associada ao AlzheimerUS 3 sites in the US

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

MapLight Therapeutics

📍 Doral, Miami👥 210 participants📅 Completion: 2029-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlzheimer DiseaseUS 7 sites in the US

Dominantly Inherited Alzheimer Network (DIAN)

Washington University School of Medicine

📍 Boston, Indianapolis, Jacksonville, Pittsburgh, Providence, Seattle, St Louis👥 700 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Esophageal Squamous Cell CarcinomaUS 4 sites in the US

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Merck Sharp & Dohme LLC

📍 East Syracuse, Los Angeles, Pittsburgh, Tucson👥 230 participants📅 Completion: 2029-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Psicose Associada a Doenca de AlzheimerUS 59 sites in the US

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

📍 Anaheim, Atlanta, Clermont, Cutler Bay, Cypress, Daytona Beach, Doral, Farmington👥 800 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Esclerose Multipla RecidivanteUS 92 sites in the US

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

Sanofi

📍 Abington, Alexandria, Altamonte Springs, Baton Rouge, Birmingham, Boca Raton, Boston, Bradenton👥 1600 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Esclerose Multipla Secundaria ProgressivaUS 102 sites in the US

A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sanofi

📍 Albuquerque, Alexandria, Altamonte Springs, Amherst, Aurora, Baltimore, Baton Rouge, Berkeley👥 900 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Alzheimer Disease PsychosisUS 31 sites in the US

A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals Inc.

📍 Abington, Aventura, Chandler, Costa Mesa, Cypress, Daytona Beach, Doral, Fresno👥 1074 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Non Small Cell Lung CancerUS 11 sites in the US

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

Merck Sharp & Dohme LLC

📍 Burbank, Corvallis, Grand Junction, Hattiesburg, Jacksonville, Louisville, Minneapolis, Phoenix👥 614 participants📅 Completion: 2030-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3hr Positive Her2 Negative Breast CancerUS 44 sites in the US

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Merck Sharp & Dohme LLC

📍 Altamonte Springs, Aurora, Baltimore, Baton Rouge, Boston, Brooklyn, Chandler, Charlotte👥 1200 participants📅 Completion: 2031-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Non Small Cell Lung CancerUS 13 sites in the US

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)

Merck Sharp & Dohme LLC

📍 Albany, Bakersfield, Beverly Hills, Billings, Cincinnati, Houston, Kansas City, Lancaster👥 600 participants📅 Completion: 2031-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Adenocarcinoma GastricoAdenocarcinoma da Juncao GastroesofagicaAdenocarcinoma EsofagicoUS 6 sites in the US

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Merck Sharp & Dohme LLC

📍 East Syracuse, Grand Rapids, Houston, Los Angeles, Pittsburgh, Tucson👥 210 participants📅 Completion: 2030-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Adenocarcinoma GastroesofagicoCancer EsofagicoUS 6 sites in the US

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Merck Sharp & Dohme LLC

📍 East Syracuse, Grand Rapids, Houston, Los Angeles, Pittsburgh, Tucson👥 160 participants📅 Completion: 2029-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Transthyretin AmyloidosisAmyloid CardiomyopathyHereditary Transthyretin PolyneuropathyUS 38 sites in the US

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Eidos Therapeutics, a BridgeBio company

📍 Atlanta, Aurora, Austin, Baltimore, Boston, Charleston, Chicago, Cleveland👥 582 participants📅 Completion: 2032-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimer DiseaseUS 76 sites in the US

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

📍 Anaheim, Atlanta, Atlantis, Belmont, Bloomfield Township, Bonita Springs, Boston, Chandler👥 406 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Non Small Cell Lung CancerUS 46 sites in the US

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

Merck Sharp & Dohme LLC

📍 Aurora, Bethlehem, Boston, Buffalo, Charlotte, Chicago, Cincinnati, Colorado Springs👥 680 participants📅 Completion: 2038-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Esclerose Sistemica Difusa CutaneaUS 14 sites in the US

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

Novartis Pharmaceuticals

📍 Ann Arbor, Boston, Chicago, Columbus, Iowa City, Los Angeles, Minneapolis, Portland👥 96 participants📅 Completion: 2032-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Dravet SyndromeUS 20 sites in the US

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Dravet Syndrome

Longboard Pharmaceuticals

📍 Aurora, Austin, Bethesda, Chicago, Fort Worth, Gulf Breeze, Houston, Little Rock👥 160 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Lennox Gastaut SyndromeEncefalopatia do Desenvolvimento e EpilepticaUS 28 sites in the US

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathies

Longboard Pharmaceuticals

📍 Atlanta, Aurora, Austin, Bethesda, Boise, Boston, Chicago, Fort Worth👥 320 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DParkinson DiseaseUS 2 sites in the US

TURN-IT FOG: A Novel Intervention to Improve Turning in People With PD and Freezing of Gait

Oregon Health and Science University

📍 Portland, Tempe👥 60 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Cancer de Mama Triplo NegativoUS 37 sites in the US

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Merck Sharp & Dohme LLC

📍 Albuquerque, Altamonte Springs, Athens, Baltimore, Boise, Chandler, Chicago, Clinton👥 1000 participants📅 Completion: 2030-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Endometrial CancerUS 43 sites in the US

A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

Merck Sharp & Dohme LLC

📍 Albuquerque, Anchorage, Bethlehem, Boston, Centerville, Chicago, Columbus, Covington👥 1123 participants📅 Completion: 2032-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Triple Negative Breast Cancerhr Low Positive Her2 Negative Breast CancerUS 49 sites in the US

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Merck Sharp & Dohme LLC

📍 Abilene, Altamonte Springs, Baltimore, Burbank, Charleston, Cincinnati, Denver, Fort Myers👥 2400 participants📅 Completion: 2034-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimer DiseaseUS 24 sites in the US

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)

Bristol-Myers Squibb

📍 Albany, Amherst, Buffalo, Chicago, Colorado Springs, Farmington Hills, Fort Myers, Fullerton👥 586 participants📅 Completion: 2029-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimer DiseaseUS 25 sites in the US

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)

Bristol-Myers Squibb

📍 Atlantis, Aventura, Basalt, Beaumont, Chicago, Columbus, Cordova, Dayton👥 586 participants📅 Completion: 2029-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Encefalopatia do Desenvolvimento e EpilepticaUS 4 sites in the US

A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants With DEE Followed by an Open-Label Extension

Praxis Precision Medicines

📍 Chevy Chase, Gulf Breeze, La Jolla, Roseville👥 160 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimer DiseaseUS 21 sites in the US

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Bristol-Myers Squibb

📍 Anaheim, Bennington, El Paso, Gaithersburg, La Jolla, Las Vegas, Miami, Middletown👥 352 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Multiple SclerosisUS 9 sites in the US

A Phase II, Randomized, Open-label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients With Multiple Sclerosis

Hoffmann-La Roche

📍 Baltimore, Carlsbad, Fort Collins, Knoxville, Maitland, Seattle, Syracuse, Tampa👥 182 participants📅 Completion: 2030-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alzheimers DiseaseUS 31 sites in the US

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

Hoffmann-La Roche

📍 Chicago, Columbus, Dallas, Decatur, Edinburg, Greensboro, Honolulu, Houston👥 800 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Parkinsons DiseaseUS 29 sites in the US

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

Hoffmann-La Roche

📍 Amherst, Atlantis, Boca Raton, Boston, Canton, Charlottesville, Cleveland, Commack👥 900 participants📅 Completion: 2031-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Cancer de Colo do UteroUS 8 sites in the US

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Merck Sharp & Dohme LLC

📍 Eugene, Fort Worth, Knoxville, Las Vegas, Miami Beach, New York, Shreveport, Tyler👥 1023 participants📅 Completion: 2031-10

View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Neurology clinical trialsrecruiting in the United States

Evaluation and Treatment of Neurosurgical Disorders

Microglial Activation PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2

Pilot Intervention With Near Infrared Stimulation: Revitalizing Cognition in Older Adults and Those With Parkinson Disease

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

What is Sleep's Role in Alzheimer's Disease? Insight From Healthy Aging

Cognitive Training to Reduce Incidence of Cognitive Impairment in Older Adults

The BEACoN Study- Biomarker Exploration in Aging, Cognition and Neurodegeneration

Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia

Stimulation of the External Pallidal Segment for Insomnia in Patients With Parkinson's Disease

Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions

Investigating Inhibitory Control Networks in Parkinson's Disease

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Promoting Independence With Compensatory Cognitive Rehabilitation: A Pilot Clinical Trial for Early-Stage Alzheimer's Disease

Depression Treatment and Aβ Dynamics: A Study of Alzheimer's Disease Risk (ABD Study)

Decision-Making Experiences for Culturally Inclusive Dementia Engagement: Dyads and Families (DECIDE: Dyads and Families)

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)

Plasticity of Motor Systems in Early Stage Parkinson's Disease

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers

Effects of Blood Pressure on Cognition and Cerebral Blood Flow in Parkinson Disease

The Impact of Depression and Preclinical Alzheimer Disease on Driving Among Older Adults (Depression and Driving)

Udall Project 1 Aim 4

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

Losing Specificity: the Role of the Locus Coeruleus in Age-related Distractibility

Hybrid Efficacy-effectiveness Trial to Promote Goals-of-care Discussions for Patients With Alzheimer's Disease and Related Dementias and Their Family Caregivers

Development of a Personalized Intervention to Motivate Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

Exercise for Cognitive Excellence in Parkinson's Disease

A Novel Intervention to Improve Care for Older Sexual and Gender Minority (SGM) Adults With Serious Illness and Especially Those With Alzheimer's Disease and Related Dementias (ADRD)

Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders (ENHANCE)

Goal Setting to Promote Physical Activity Adherence in Midlife to Reduce Risk of Alzheimer's Disease and Related-Dementias: A Randomized Mechanistic Proof-Of-Concept Trial

Gamma-Music Based Intervention for Mild Alzheimer's Disease

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease

A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease

PET Imaging Evaluation of [11C]SY08

Over-the-counter Hearing Aids and Mild Cognitive Impairment

Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

Utilization of Robotic EksoSkeleton to Achieve High Dosing, Intensity, and Complexity of Gait in Treatment of People With Parkinson's Disease

Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision

A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics

Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System

Proof of Concept of the Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

Beta Amyloid PET Imaging for Alzheimer Disease: [18F]-Fluselenamyl (Alternative Vehicle) Comparison With [11C]-PIB (FSA-PIB AD)

Genetics and Aerobic Exercise to Slow Parkinson's Disease (GEARS) Trial

Social Prescription for Loneliness in Community-based Group Exercise Classes for People With Parkinson Disease

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Revealing the Action Regulation Mechanisms in the Human Brain

Blood Flow Restriction for Optimizing Balance in Parkinson's Disease

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

Remote Monitoring Using Commercially Available Activity Trackers and Computer Vision Provides a Holistic, Low-cost Assessment of Parkinson's Disease Symptoms

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Impact of Wearable Biofeedback for the Rehabilitation and Tele-rehabilitation of Neurogenic Dysphagia

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Duke/UNC Alzheimer's Disease Center Clinical Cohort

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

A Multicenter, Sham-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Responses Following Stereotactic Intracranial Implantation of DSP-1083 Into Subjects With Parkinson's Disease

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants With Parkinson's Disease

Mechanisms of Mindfulness for Cognition in Early-Stage Alzheimer's Disease

Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson's Disease

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Transitional Care for Skilled Nursing Facility Patients With Alzheimer's Disease and Related Dementias and Their Caregivers: a Cluster Randomized Trial

Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease

Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease

HEARS Neuropsychiatric Symptoms & Hearing Loss: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)

exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Evaluating and Optimizing Just-In-Time Adaptive Interventions (JITAIs) in a Digital Mental Health Intervention (Wysa for Chronic Pain) for Middle-Aged and Older Adults With Chronic Pain

Imaging Core Aim 2, and Udall Project 2 Aim 2

Neurology clinical trials
recruiting in the United States